{"id":"https://openalex.org/W2109010689","doi":"https://doi.org/10.1371/journal.pone.0009390","title":"Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection","display_name":"Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection","publication_year":2010,"publication_date":"2010-02-22","ids":{"openalex":"https://openalex.org/W2109010689","doi":"https://doi.org/10.1371/journal.pone.0009390","mag":"2109010689","pmid":"https://pubmed.ncbi.nlm.nih.gov/20186346","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2826423"},"language":"en","primary_location":{"id":"doi:10.1371/journal.pone.0009390","doi":"https://doi.org/10.1371/journal.pone.0009390","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0009390","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009390&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS ONE","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009390&type=printable","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033471393","display_name":"Nancie M. Archin","orcid":"https://orcid.org/0000-0002-7938-0389","observed_orcids":["https://orcid.org/0000-0002-7938-0389"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancie M. Archin","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071755573","display_name":"MA Cheema","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manzoor Cheema","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014120435","display_name":"Daniel Parker","orcid":"https://orcid.org/0000-0001-8512-1044","observed_orcids":["https://orcid.org/0000-0001-8512-1044"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Parker","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111904914","display_name":"Ann P. Wiegand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Wiegand","raw_affiliation_strings":["HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029030800","display_name":"Ronald J. Bosch","orcid":"https://orcid.org/0000-0002-1774-4140","observed_orcids":["https://orcid.org/0000-0002-1774-4140"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald J. Bosch","raw_affiliation_strings":["Harvard School of Public Health, Boston, Massachusetts, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard School of Public Health, Boston, Massachusetts, United States of America","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065227576","display_name":"John M. Coffin","orcid":"https://orcid.org/0000-0003-3856-762X","observed_orcids":["https://orcid.org/0000-0003-3856-762X"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Coffin","raw_affiliation_strings":["HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024560316","display_name":"Joseph J. Eron","orcid":"https://orcid.org/0000-0002-4938-0644","observed_orcids":["https://orcid.org/0000-0002-4938-0644"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Eron","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024262342","display_name":"Myron S. Cohen","orcid":"https://orcid.org/0000-0001-5917-9664","observed_orcids":["https://orcid.org/0000-0001-5917-9664"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Myron Cohen","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008716404","display_name":"David M. Margolis","orcid":"https://orcid.org/0000-0001-5714-0002","observed_orcids":["https://orcid.org/0000-0001-5714-0002"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David M. Margolis","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5008716404"],"corresponding_institution_ids":["https://openalex.org/I114027177"],"apc_list":{"value":2382,"currency":"USD","value_usd":2382},"apc_paid":{"value":2382,"currency":"USD","value_usd":2382},"fwci":7.3153,"has_fulltext":true,"cited_by_count":152,"citation_normalized_percentile":{"value":0.98219116,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"5","issue":"2","first_page":"e9390","last_page":"e9390"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.007300000172108412,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11381","display_name":"Infectious Diseases and Tuberculosis","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.675000011920929},{"id":"https://openalex.org/keywords/residual-viremia","display_name":"residual viremia","score":0.8600000143051147},{"id":"https://openalex.org/keywords/valproic-acid","display_name":"valproic acid","score":0.8159999847412109},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9549999833106995},{"id":"https://openalex.org/keywords/raltegravir","display_name":"raltegravir","score":0.9710000157356262},{"id":"https://openalex.org/keywords/enfuvirtide","display_name":"enfuvirtide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/antiretroviral-therapy-intensification","display_name":"antiretroviral therapy intensification","score":0.9279999732971191},{"id":"https://openalex.org/keywords/proviral-latency","display_name":"proviral latency","score":0.7590000033378601},{"id":"https://openalex.org/keywords/low-level-viremia","display_name":"low-level viremia","score":0.7789999842643738}],"concepts":[{"id":"https://openalex.org/C2776185481","wikidata":"https://www.wikidata.org/wiki/Q1425304","display_name":"Viremia","level":3,"score":0.9155179262161255},{"id":"https://openalex.org/C2778037500","wikidata":"https://www.wikidata.org/wiki/Q423327","display_name":"Enfuvirtide","level":5,"score":0.7738827466964722},{"id":"https://openalex.org/C2777172819","wikidata":"https://www.wikidata.org/wiki/Q240642","display_name":"Valproic Acid","level":3,"score":0.7471047639846802},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5405792593955994},{"id":"https://openalex.org/C2780404665","wikidata":"https://www.wikidata.org/wiki/Q421552","display_name":"Raltegravir","level":5,"score":0.5388853549957275},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5352393388748169},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.4874427616596222},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3964320719242096},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.36753782629966736},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.34617879986763},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.3403306007385254},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.21731075644493103},{"id":"https://openalex.org/C2776258796","wikidata":"https://www.wikidata.org/wiki/Q5590520","display_name":"Gp41","level":4,"score":0.0},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.0},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000068898","descriptor_name":"Raltegravir Potassium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077560","descriptor_name":"Enfuvirtide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014766","descriptor_name":"Viremia","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D015496","descriptor_name":"CD4-Positive T-Lymphocytes","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015700","descriptor_name":"HIV Envelope Protein gp41","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016516","descriptor_name":"CD4-CD8 Ratio","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":8,"locations":[{"id":"doi:10.1371/journal.pone.0009390","doi":"https://doi.org/10.1371/journal.pone.0009390","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0009390","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009390&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS ONE","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2826423","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2826423","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS One","raw_type":"Text"},{"id":"pmid:20186346","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20186346","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PloS one","raw_type":"Clinical Trial"},{"id":"pmh:cdr.lib.unc.edu:h702qf23w","doi":null,"is_oa":true,"landing_page_url":"https://doi.org/10.17615/2ek5-wr30","pdf_url":"https://doi.org/10.17615/2ek5-wr30","source":{"id":"https://openalex.org/S4306401075","display_name":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114027177","host_organization_name":"University of North Carolina at Chapel Hill","host_organization_lineage":["https://openalex.org/I114027177"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"PloS One, 5(2)","raw_type":"Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.356.2875","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.356.2875","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/8b/3c/PLoS_One_2010_Feb_23_5(2)_e9390.tar.gz","raw_type":"text"},{"id":"pmh:oai:dash.harvard.edu:1/4584795","doi":null,"is_oa":true,"landing_page_url":"http://nrs.harvard.edu/urn-3:HUL.InstRepos:4584795","pdf_url":null,"source":{"id":"https://openalex.org/S4306401540","display_name":"Digital Access to Scholarship at Harvard (DASH) (Harvard University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I136199984","host_organization_name":"Harvard University","host_organization_lineage":["https://openalex.org/I136199984"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:e0fc383383ed497e8bc9f9a01a91cd7c","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e0fc383383ed497e8bc9f9a01a91cd7c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"PLoS ONE, Vol 5, Iss 2, p e9390 (2010)","raw_type":"article"},{"id":"doi:10.17615/2ek5-wr30","doi":"https://doi.org/10.17615/2ek5-wr30","is_oa":true,"landing_page_url":"https://doi.org/10.17615/2ek5-wr30","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.1371/journal.pone.0009390","doi":"https://doi.org/10.1371/journal.pone.0009390","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0009390","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009390&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS ONE","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8299999833106995,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1939027404","display_name":null,"funder_award_id":"AI50410","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G206438753","display_name":null,"funder_award_id":"U54 RR 024383","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G2307004170","display_name":null,"funder_award_id":"R00046","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"},{"id":"https://openalex.org/G2638151518","display_name":null,"funder_award_id":"AI 45297","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G325665968","display_name":null,"funder_award_id":"AI 064074","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G4449209241","display_name":"Repression of HIV Transcription-A Pathway to Quiescence","funder_award_id":"R01AI045297","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G5920159762","display_name":"Clearing Persistently  HIV-Infected CD4+ T Lymphocytes","funder_award_id":"R01AI064074","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G7609103129","display_name":"Repression of HIV Transcription: from mechanism to anti-latency therapies","funder_award_id":"R56AI045297","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"},{"id":"https://openalex.org/G9000075494","display_name":null,"funder_award_id":"AI50410","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000894295","display_name":"The University of North Carolina Center for AIDS Research","funder_award_id":"P30AI050410","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"}],"funders":[{"id":"https://openalex.org/F4320306095","display_name":"American Cancer Society","ror":"https://ror.org/02e463172"},{"id":"https://openalex.org/F4320306402","display_name":"F. M. Kirby Foundation","ror":"https://ror.org/03kz2rg33"},{"id":"https://openalex.org/F4320306493","display_name":"Abbott Laboratories","ror":"https://ror.org/0052svj16"},{"id":"https://openalex.org/F4320310693","display_name":"Deutsches Krebsforschungszentrum","ror":"https://ror.org/04cdgtt98"},{"id":"https://openalex.org/F4320314616","display_name":"James N. Kirby Foundation","ror":"https://ror.org/0367ekx87"},{"id":"https://openalex.org/F4320316438","display_name":"Georgia Clinical and Translational Science Alliance","ror":"https://ror.org/034hw7m59"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"},{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"},{"id":"https://openalex.org/F4320337677","display_name":"Center for AIDS Research, University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2109010689.pdf","grobid_xml":"https://content.openalex.org/works/W2109010689.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1963802821","https://openalex.org/W1991502041","https://openalex.org/W1996604523","https://openalex.org/W2004223360","https://openalex.org/W2051879794","https://openalex.org/W2084907069","https://openalex.org/W2112874784","https://openalex.org/W2117211286","https://openalex.org/W2117962018","https://openalex.org/W2119974226","https://openalex.org/W2120488252","https://openalex.org/W2121443169","https://openalex.org/W2124114936","https://openalex.org/W2124151594","https://openalex.org/W2125878780","https://openalex.org/W2149767613","https://openalex.org/W2158934536","https://openalex.org/W2166861522","https://openalex.org/W2170473457"],"related_works":["https://openalex.org/W1963802821","https://openalex.org/W2113669930","https://openalex.org/W2166861522","https://openalex.org/W1936344549","https://openalex.org/W2119974226","https://openalex.org/W4239631824","https://openalex.org/W2124259970","https://openalex.org/W2148835789","https://openalex.org/W2053071621","https://openalex.org/W2149767613"],"abstract_inverted_index":{"BACKGROUND:":[0],"Human":[1],"immunodeficiency":[2],"virus":[3],"(HIV)":[4],"infection":[5,25],"that":[6,20,285],"persists":[7],"despite":[8],"antiretroviral":[9],"therapy":[10,220],"(ART)":[11],"is":[12,27],"a":[13,118,174,178],"daunting":[14],"problem.":[15],"Given":[16],"the":[17,30,40,192,201,228,257],"limited":[18],"evidence":[19],"resting":[21],"CD4+":[22],"T":[23],"cell":[24],"(RCI)":[26],"affected":[28],"by":[29,97,104,238],"histone":[31],"deacetylase":[32],"(HDAC)":[33],"inhibitor":[34],"valproic":[35],"acid":[36],"(VPA),":[37],"we":[38],"measured":[39,96,237],"stability":[41],"of":[42,120,127,138,160,183,194,200,206,227,230,244,259],"RCI":[43,94,121,166,184],"and":[44,158,171,196,246,249,264],"residual":[45],"viremia":[46,101,236],"in":[47,93,168,173,177,188,277],"patients":[48,114,143,203],"who":[49],"added":[50,74,145],"VPA":[51,76,161,215,245,248],"with":[52,60,69,156,279],"or":[53,57,61,86,217,232,251,261,276,282],"without":[54,62],"raltegravir":[55],"(RAL),":[56],"enfuvirtide":[58],"(ENF)":[59],"VPA,":[63,128],"to":[64,135,146,211,254],"standard":[65,116],"ART.":[66],"METHODS:":[67],"Patients":[68],"plasma":[70,106],"HIV":[71,107],"RNA<50":[72],"c/mL":[73],"sustained-release":[75],"(Depakote":[77],"ER)":[78],"twice":[79,84,90],"daily,":[80,85],"RAL":[81,195,231],"400":[82],"mg":[83],"ENF":[87,144,157,233,252],"90":[88],"mcg":[89],"daily.":[91],"Change":[92],"was":[95,102,122,186,224],"outgrowth":[98],"assays.":[99],"Low-level":[100],"quantitated":[103],"single-copy":[105],"RNA":[108],"assay":[109],"(SCA).":[110],"RESULTS:":[111],"In":[112,141,198],"three":[113],"on":[115,152,165,234],"ART":[117,148,281],"depletion":[119,182],"observed":[123],"after":[124,191],"16":[125],"weeks":[126,137],"but":[129],"this":[130,204],"effect":[131,151,164,207,226],"waned":[132],"over":[133],"up":[134],"96":[136],"further":[139],"VPA.":[140,197],"two":[142],"stable":[147],"had":[149,162],"no":[150,163,225],"RCI.":[153],"Simultaneous":[154],"intensification":[155],"addition":[159,193,229,243],"frequency":[167,258],"one":[169],"patient,":[170],"resulted":[172],"46%":[175],"decline":[176],"second.":[179],"No":[180],"significant":[181],"(>50%)":[185],"seen":[187],"six":[189],"volunteers":[190],"4":[199],"6":[202],"lack":[205],"might":[208],"be":[209,291],"attributed":[210],"intermittent":[212,218,263],"viremia,":[213],"low":[214],"levels,":[216],"study":[219],"adherence.":[221],"Overall,":[222],"there":[223],"low-level":[235,265],"SCA.":[239],"CONCLUSIONS:":[240],"The":[241],"prospective":[242],"RAL,":[247],"ENF,":[250],"failed":[253],"progressively":[255],"reduce":[256],"RCI,":[260],"ablate":[262],"viremia.":[266],"New":[267],"approaches":[268],"such":[269],"as":[270],"more":[271],"potent":[272],"HDAC":[273],"inhibition,":[274],"alone":[275],"combination":[278],"intensified":[280],"other":[283],"agents":[284],"may":[286],"disrupt":[287],"proviral":[288],"latency":[289],"must":[290],"pursued.":[292]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":15},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":21},{"year":2012,"cited_by_count":18}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}